TScan Therapeutics to Participate in Upcoming Investor Conferences
TScan Therapeutics, Inc. (Nasdaq: TCRX) has announced its participation in two major investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) has announced its participation in two major investor conferences. The Cowen 42nd Annual Health Care Conference will feature a virtual discussion on March 9, 2022, at 9:10 a.m. ET. Subsequently, TScan will participate in the Barclays Global Healthcare Conference with a fireside chat on March 16, 2022, at 8:30 a.m. ET in Miami Beach, FL. Webcasts of both sessions will be available on TScan's website, with archived replays accessible for 30 days post-event.
Details
News Market Reaction – TCRX
The recorded move for TCRX in the trading session of this news was +0.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:
- Cowen 42nd Annual Health Care Conference; the Cell Therapy Panel discussion will be held virtually on Wednesday, March 9, 2022 at 9:10 a.m. ET
- Barclays Global Healthcare Conference; the fireside chat will be held in Miami Beach, FL on Wednesday, March 16, 2022 at 8:30 a.m. ET
Webcasts of each session will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcasts will be available on the Company’s website for 30 days following the events.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, one of the most extensive collections of known and novel solid tumor targets across different HLA types in the TCR field.
Contacts:
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
jallaire@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.